Brain cancer battle: new combo therapy tested in phase 3 trial
Disease control
Recruiting now
This study tests whether adding the immunotherapy drug pembrolizumab to standard treatment (tumor-treating fields plus chemotherapy) helps people with newly diagnosed glioblastoma live longer. About 741 adults will be randomly assigned to receive either the active drug or a place…
Phase: PHASE3 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated May 17, 2026 03:13 UTC